Background: The pharmacokinetics of factor VIII replacement therapy in preschool previously treated patients (PTPs) with hemophilia A have not been well characterized. Objectives: To assess the pharmacokinetics, efficacy and safety of a plasma-free recombinant FVIII concentrate, ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method, rAHF-PFM], in children < 6 years of age with severe hemophilia. Patients/methods: Fifty-two boys, one girl, mean (+/- SD) age 3.1 +/- 1.5 years and >= 50 days of prior FVIII exposure, were enrolled in a prospective study of ADVATE rAHF-PFM at 23 centers. Results: The mean terminal phase half-life (t(1/2)) was 9.88 +/- 1.89 h, and the mean adjusted in vivo recovery (IVR) was 1.90 +/- 0.43 IU dL(-1) (IU kg(-1))(-1). Over the 1-6-year age range, t(1/2) of rAHF-PFM increased by 0.40 h year(-1). IVR increased by 0.095IU dL(-1)(IU kg(-1))(-1) (kg m(-2))(-1) in relation to body mass index (BMI). Patients primarily received prophylaxis. Median (range) annual joint bleeds were 0.0 (0.0-5.8), 0.0 (0.0-6.1) and 14.2 (0.0-34.5) for standard prophylaxis, modified prophylaxis and on-demand treatment, respectively. Bleeds were managed in 90% (319/354) of episodes with one or two rAHF-PFM infusions; response was rated excellent/good in 93.8% of episodes. Over a median 156 exposure days, no FVIII inhibitors were detected and no related severe adverse events or unusual non-serious adverse events were seen. Conclusions: Children < 6 years of age appear to have shorter FVIII t(1/2) and lower IVR values than older subjects. However, these parameters increased with age (t(1/2)) and BMI (adjusted IVR), respectively. rAHF-PFM was clinically effective and well tolerated, with no signs of increased immunogenicity in previously treated young children with hemophilia A.
机构:
CSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USACSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USA
Zhang, Y.
Roberts, J.
论文数: 0引用数: 0
h-index: 0
机构:
CSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USACSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USA
Roberts, J.
Tortorici, M.
论文数: 0引用数: 0
h-index: 0
机构:
CSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USACSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USA
Tortorici, M.
Veldman, A.
论文数: 0引用数: 0
h-index: 0
机构:
CSL Behring GmbH, Global Clin Res & Dev, Marburg, GermanyCSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USA
Veldman, A.
St Ledger, K.
论文数: 0引用数: 0
h-index: 0
机构:
CSL Behring, Global Clin Res & Dev, King Of Prussia, PA USACSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USA
St Ledger, K.
Feussner, A.
论文数: 0引用数: 0
h-index: 0
机构:
CSL Behring GmbH, Dept Preclin Res & Dev, Marburg, GermanyCSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USA
Feussner, A.
Sidhu, J.
论文数: 0引用数: 0
h-index: 0
机构:
CSL Ltd, Clin Pharmacol & Early Dev, Parkville, Vic, AustraliaCSL Behring, Clin Pharmacol & Early Dev, 1020 First Ave, King Of Prussia, PA 19406 USA